Forecast Quotations
Forecast Quotes from:
-
Accepted Quotes
We've accepted the fact that the earnings growth for the quarter is around 20, 21 percent year-over-year for the S&P. But there's been this behind the scenes look or under the surface look at revenue. And we haven't got the best of forecasts for the second half of the year in many companies going forward. And if you don't have that pristine look -- where you come in this earnings season totally clean -- you've gotten battered. And I can't even name more than a handful of stocks that have come through.
-
Aggregate Quotes
We believe that these initiatives, together with improved cash flow from business operations, have enhanced our financial flexibility. We currently have sufficient resources to retire the remaining '06 convertible notes at maturity and based on current forecasts we believe we will have sufficient liquidity available to satisfy the $146 million of 5% convertible notes due March 2007. As previously announced, during the first quarter of 2006 we purchased in the open market $30 million face value of our outstanding $471 million aggregate principal amount of 9.25% Senior notes due February 2008.
-
Boats Quotes
I hate that we ended up with 71 boats, but we did the right thing. I can understand why a lot of guys didn't want to go. We've got a lot of custom-built boats that cost several million dollars (and fishermen) who just didn't want to risk it in 11- to 14-foot seas forecast for later in the weekend.
-
Attempt Quotes
Given recent activity, McAfee AVERT Labs forecasts that attackers may attempt to test the viability of exploiting this vulnerability en masse, by producing a reconnaissance Trojan to identify a vulnerable user base. Exploit source code with a payload has been published. Now, the message is 'welcome to zero-day vulnerability land for many Mac OS X users' Only, Mac OS X users are less prepared, less aware and mitigation tools are less evolved.
-
Adjusted Quotes
Given our products, pipeline, and the fact that we expect no major patent expirations for the rest of this decade, Lilly is uniquely positioned to deliver sustained earnings growth. For 2006, we anticipate earnings per share of $3.10 to $3.20, which represents 8% to 12% growth compared with expected 2005 adjusted earnings. This growth rate is nearly double the average Wall Street consensus forecast for large-cap pharmaceutical companies.